Commercialisation of a novel drug discovery target critical for the development of autoimmune diseases
|Funding from Vinnova||SEK 300 000|
|Project duration||November 2017 - April 2018|
Purpose and goal
In this project the intention was to develop an academic project into a commercially viable drug discovery project. The project validated one chemical series with submicromolar affinity by developing a new assay and identified a second series via a different mechanism of action. Furthermore, we were able to show that both series have good properties to be developed into drugs and are patentable. These compounds can now be used in proof-of-concept studies to validate the target in vivo.
Expected results and effects
The supported project accelerated the scientific validation of a new target for the treatment of autoimmune diseases that will be critical to attract further funding. Within a year we expect to have a lead candidate with a validated effect in animal models. This will be critical in the discussion with big pharma companies to ensure the progress and funding of the project
Planned approach and implementation
Combining in vivo and project expertise with researchers at Karolinska Institutet with drug development expertise in Immunscape has proved beneficial for the project. The new method developed during the project enabled the validation of target inhibiting molecules. Furthermore, the evaluation and application of an alternative mechanism of action gave a new attractive therapeutic direction of the project with the possibility of faster market entry.